|
|||||
|
|
A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer |
|
| Authors: | Robin L. Jones Johanna C. Bendell David C. Smith Konstanze Diefenbach John Lettieri Oliver Boix A. Craig Lockhart Cindy O’Bryant Kathleen N. Moore |
| Affiliation: | 1. Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA 2. Sarcoma Unit, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK 3. Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA 4. Internal Medicine Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA 5. Bayer Pharma AG, Berlin, Germany 6. Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA 7. Bayer Pharma AG, Wuppertal, Germany 8. Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA 9. Department of Clinical Pharmacy, University of Colorado Cancer Center, Aurora, CO, USA 10. Stephenson Cancer Center, Oklahoma University HSC, Oklahoma City, OK, USA |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |